We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.
- Authors
Gatell, Jose; Salmon-Ceron, Dominique; Lazzarin, Adriano; Van Wijngaerden, Eric; Antunes, Francisco; Leen, Clifford; Horban, Andrzej; Wirtz, Victoria; Odeshoo, Linda; Van den Dungen, Monique; Gruber, Claudia; Ledesma, Emilio; SWAN Study Group
- Abstract
Atazanavir is a once-daily protease inhibitor (PI) for the treatment of human immunodeficiency virus (HIV) infection that has previously been studied in cohorts of treatment-naive and treatment-experienced patients. Limited data are available on the usefulness of switching from a PI-based regimen to a regimen based on a different PI, such as atazanavir, in HIV-infected patients experiencing virologic suppression but seeking regimen simplification.
- Publication
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2007, Vol 44, Issue 11, p1484
- ISSN
1537-6591
- Publication type
Journal Article
- DOI
10.1086/517497